The fall and rise of pharmacology - (Re-)defining the discipline?

Biochemical Pharmacology

Volumn 87, Issue 1, 2014, Pages 4-24

  Winquist, Raymond J ^a   Mullane, Kevin ^b   Williams, Michael ^c  

^a VERTEX PHARMACEUTICALS   (United States)

^b Profectus Pharma Consulting   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Drug discovery; Pharmacology; Receptors; Systems biology

Indexed keywords

BETA ARRESTIN; CLOZAPINE; DIAZEPAM; DRUG RECEPTOR; G PROTEIN COUPLED RECEPTOR; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; LIGAND; NEUROTRANSMITTER; ORPHAN NUCLEAR RECEPTOR; PATTERN RECOGNITION RECEPTOR; PROTEIN SERINE THREONINE KINASE; PROTEIN TYROSINE KINASE; RECEPTOR SUBTYPE; TERNARY COMPLEX FACTOR;

ALLOSTERISM; AUTORADIOGRAPHY; BIOCHEMISTRY; CLONING; CRYSTALLIZATION; DIMERIZATION; DRUG MECHANISM; DRUG SCREENING; DRUG TARGETING; ENDOCYTOSIS; EVOLUTION; GENE MAPPING; HISTORY; HUMAN GENOME; LIGAND BINDING; MEDICAL RESEARCH; MOLECULAR DYNAMICS; MUTAGENESIS; OLIGOMERIZATION; PHARMACOGENOMICS; PHARMACOLOGY; PRIORITY JOURNAL; RECEPTOR BINDING ASSAY; RECEPTOR DOWN REGULATION; RECEPTOR OCCUPANCY; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; TACHYPHYLAXIS;

DRUG DISCOVERY; PHARMACOLOGY; RECEPTORS; SYSTEMS BIOLOGY;

ANIMALS; CLONING, MOLECULAR; HUMANS; PHARMACEUTICAL PREPARATIONS; PHARMACOGENETICS; PHARMACOLOGY; RECEPTORS, CELL SURFACE;

EID: 84892370699     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2013.09.011     Document Type: Review

References (330)

1. W. Sneader Drug discovery. A history 2005 Wiley Chichester, UK
2. F. Chast A history of drug discovery C.G. Wermuth, Wermuth's the practice of medicinal chemistry 3rd ed. 2008 Elsevier Academic Press Burlington, MA 3 62
3. E. Ravina The evolution of drug discovery 2011 Wiley-VCH Weinheim
4. H.P. Rang The development of the pharmaceutical industry R.G. Hill, H.P. Rang, Drug discovery and development. Technology in transition 2nd Ed 2013 Churchill Livingstone London 3 18
5. J. Manyika, M. Chui, B. Brown, J. Bughin, R. Dobbs, and C. Roxburgh et al. Big data: the next frontier for innovation, competition, and productivity 2011 McKinsey Global Institution http://www.mckinsey.com/insights/business- technology/big-data-the-next-frontier-for-innovation
6. S. Brenner An interview with. Sydney Brenner. Interview by Errol C. Friedberg Nat Rev Mol Cell Biol 9 2008 8 9
7. P.C. Jobe, L.E. Adams-Curtis, T.F. Burks, R.W. Fuller, C.C. Peck, and R.R. Ruffolo et al. The essential role of integrative biomedical sciences in protecting and contributing to the health and well being of our nation Physiologist 37 1994 79 84
8. Horrabin DF: Modern biomedical research: an internally self consistent universe with little contact with medical reality? Nat Rev Drug Discov 2 2003 151 154
9. FDA Innovation/stagnation. Challenge and opportunity on the critical path to new medical products 2004 FDA Bethesda, MD, USA http://www.fda.gov/ ScienceResearch/SpecialTopics/CriticalPathInitiative/ CriticalPathOpportunitiesReports/ucm077262.htm
10. G. Duyk Attrition and translation Science 302 2003 603 605 (Pubitemid 37310908)
11. M. Williams Systems and integrative biology as alternative guises for pharmacology: prime time for an iPharm concept? Biochem Pharmacol 70 2005 1707 1716 (Pubitemid 41612001)
12. S.H. Woolf The meaning of translational research and why it matters J Am Med Assoc 299 2008 211 213
13. M. Wehling Assessing the translatability of drug projects: what needs to be scored to predict success? Nat Rev Drug Discov 8 2009 541 546
14. L. Hood, J.R. Heath, M.E. Phelps, and B. Lin Systems biology and new technologies enable predictive and preventative medicine Science 306 2004 640 643 (Pubitemid 39440903)
15. R. Iyengar, S. Zhao, S.W. Chung, D.E. Mager, and J.M. Gallo Merging systems biology with pharmacodynamics Sci Transl Med 4 2012 126ps7
16. P.H. van der Graaf, and N. Benson Systems pharmacology: bridging systems biology and pharmacokinetics-pharmacodynamics (PKPD) in drug discovery and development Pharm Res 28 2011 1460 1464
17. L. Cucurull-Sanchez, K.G. Spink, and S.A. Moschos Relevance of systems pharmacology in drug discovery Drug Discov Today 17 2012 665 670
18. M.J. Keiser, J.J. Irwin, and B.K. Shiochet The chemical basis of pharmacology Biochemistry 49 2010 10267 10276
19. E.E. Schadt, S.H. Friend, and D.A. Shaywitz A network view of disease and compound screening Nat Rev Drug Discov 8 2009 286 295
20. L.I. Furlong Human diseases through the lens of network biology Trends Genetics 29 2013 150 159
21. P. Csermely, T. Korcsmáros, H.J.M. Kiss, G. London, and R. Nussinov Structure and dynamics of molecular networks: a novel paradigm of drug discovery: a comprehensive review Pharmacol Ther 138 2013 333 408
22. A.-L. Barabási, N. Gulbahce, and J. Loscalzo Network medicine: a network-based approach to human disease Nat Rev Genet 12 2011 56 68
23. P.K. Sorger, S.R.B. Allerheiligen, D.R. Abernethy, R.B. Altman, K.L.R. Brouwer, and A. Califano et al. Quantitative and systems pharmacology in the post-genomic era: new approaches to discovering drugs and understanding therapeutic mechanisms 2011 http://isp.hms.harvard.edu/wordpress/wp-content/ uploads/2011/10/NIH-Systems-Pharma-Whitepaper-Sorger-et-al-2011.pdf
24. M. Rogers, P. Lyster, and R. Okita NIH support for the emergence of quantitative and systems pharmacology CPT: Pharmacometr Syst Pharmacol 2 2013 e37
25. J. Black A life in new drug research Br J Pharmacol 160 Suppl. 1 2010 S15 S25
26. M. Williams Productivity shortfalls in drug discovery: contributions from the preclinical sciences? J Pharmacol Exp Ther 336 2011 3 8
27. B. Munos Lessons from 60 years of pharmaceutical innovation Nat Rev Drug Discov 8 2009 959 968
28. F. Pammolli, L. Magazzini, and M. Riccaboni The productivity crisis in pharmaceutical R & D Nat Rev Drug Discov 10 2011 428 438
29. J.W. Scannell, A. Blanckley, H. Boldon, and B. Warrington Diagnosing the decline in pharmaceutical R&D efficiency Nat Rev Drug Discov 11 2012 191 200
30. K.A. Giuliano, R.L. DeBiasio, R.T. Dunlay, A. Gough, J.M. Volosky, and J. Zock et al. High-content screening: a new approach to easing key bottlenecks in the drug discovery process J Biomol Screen 2 1997 249 259 (Pubitemid 127690015)
31. L. Mitscher Traditional medicines Comp Med Chem II 1 2007 406 430
32. P. Goldman Herbal medicines today and the roots of modern pharmacology Ann Intern Med 135 2001 594 600 (Pubitemid 33010195)
33. G.M. Cragg, P.G. Grothaus, and D.J. Newman Natural products in drug discovery: recent advances V. Cechinel-Filho, Plant bioactives and drug discovery: principles, practice, and perspectives 4th ed. 2012 Wiley Hoboken 1 42
34. J. Liebenau Evolution of the pharmaceutical industry Comp Med Chem I 1 1990 81 98
35. A.D. Chandler Shaping the industrial century. The remarkable story of the modern chemical and pharmaceutical industries 2005 Harvard University Press Cambridge, MA 177 259
36. J.L. Furman, and M. MacGarvie Academic collaboration and organizational innovation: the development of research capabilities in the US pharmaceutical industry, 1927-1946 Ind Corp Change 18 2009 929 961
37. J.P. Swann Academic scientists and the pharmaceutical industry 1988 Johns Hopkins University Press Baltimore, MD
38. A.J. Stevens, J.J. Jensen, K. Wyller, and P.C. Kilgore et al. The role of public-sector research in the discovery of drugs and vaccines New Eng. J Med 364 2011 535 541
39. J.L. Furman, and M. MacGarvie When the pill peddlers met the scientists: the antecedents and implications of early collaborations between US pharmaceutical firms and universities Essay Econ Bus History XXVI 2008 138 146
40. J. Frearson, and P. Wyatt Drug discovery in academia - the third way? Exp Opin Drug Discov 5 2010 909 919
41. D.M. Huryn, L.O. Resnick, and P. Wipf Contributions of academic laboratories to the discovery and development of chemical biology tools J Med Chem 56 2013 7161 7176
42. J. LaMattina Drug truths: dispelling the myths about pharma R&D 2008 Wiley Hoboken
43. F. Prinz, T. Schlange, and K. Asadullah Believe it or not: how much can we rely on published data on potential drug targets? Nat Rev Drug Discov 10 2011 712 713
44. C.G. Begley, and L.M. Ellis Raise standards for preclinical cancer research Nature 483 2012 531 533
45. A. Mobley, S.K. Linder, R. Braeuer, L.M. Ellis, and L. Zwelling A survey on data reproducibility in cancer research provides insights into our limited ability to translate findings from the laboratory to the clinic PLoS ONE 8 2013 e63221
46. F. Yu, T. Takahashi, J. Moriya, K. Kawaura, J. Yamakawa, and K. Kusaka et al. Traditional Chinese medicine and Kampo: a review from the distant past for the future J Int Med Res 34 2006 231 239 (Pubitemid 44057265)
47. J. van der Greef, H. van Wietmarschen, J. Schroro, M. Wang, T. Hankemeier, and G. Xu Systems biology-based diagnostic principles as pillars of the bridge between chinese and western medicine Planta Med 76 2010 2036 2047
48. E. Chan, M. Tan, J. Xin, S. Sudarsanam, and D.E. Johnson Interactions between traditional Chinese medicines and Western therapeutics Curr Opin Drug Discov Dev 13 2010 50 65
49. M.S. Butler The role of natural product chemistry in drug discovery J Nat Prod 64 2004 2141 2153 (Pubitemid 40092578)
50. A.D. Kinghorn, Y.-W. Chin, and S.M. Swanson Discovery of natural product anticancer agents from biodiverse organisms Curr Opin Drug Discov Dev 12 2009 189 196
51. J. Clardy, M.A. Fischbach, and C.T. Walsh New antibiotics from bacterial natural products Nat Biotechnol 24 2006 1541 1550 (Pubitemid 44967478)
52. H.M. Garraffo, T.F. Spande, and M. Williams Epibatidine: from frog alkaloid to analgesic drug candidates. A testimonial to "True Grit"! Heterocycles 79 2009 207 217
53. U. Klotz Ziconotide - a novel neuron-specific calcium channel blocker for the intrathecal treatment of severe chronic pain - a short review Int J Clin Pharmacol Ther 44 2006 478 483 (Pubitemid 44540941)
54. R.L. Medcalf Desmoteplase: discovery, insights and opportunities for ischemic stroke Br J Pharmacol 165 2012 75 89
55. R.P. Rubin A brief history of great discoveries in pharmacology: in celebration of the centennial anniversary of the founding of the American Society of Pharmacology and Experimental Therapeutics Pharmacol Rev 59 2007 289 359
56. S.H.E. Kaufmann Paul Ehrlich: founder of chemotherapy Nat Rev Drug Discov 7 2008 373 (Pubitemid 351619105)
57. K. Strebhardt, and A. Ullrich Paul Ehrlich's magic bullet concept: 100 years of progress Nat Rev Cancer 8 2008 473 480 (Pubitemid 351752547)
58. M.R. Bennett The concept of transmitter receptors: 100 years on Neuropharmacology 39 2000 523 546 (Pubitemid 30089303)
59. A.-H. Maehle, C.-Y. Prüll, and R.F. Halliwell The emergence of the drug receptor theory Nat Rev Drug Discov 1 2002 637 641 (Pubitemid 37361525)
60. T. Kenakin Principles: receptor theory in pharmacology Trends Pharmacol Sci 26 2004 186 192 (Pubitemid 38519909)
61. H.P. Rang The receptor concept; pharmacology's big idea Br J Pharmacol 147 2006 S9 S16
62. J.M. Norman William Withering and the Purple Foxglove: a bicentennial tribute J. Clin Pharmacol 25 1985 479 483
63. F.L. Holmes From elective affinities to chemical equilibria: Berthollet's law of mass action Chymia 8 1962 105 147
64. E.W. Lund Guldberg and Waage and the law of mass action J Chem Educ 42 1965 548 550
65. D.B. Bylund, and M. Toews Quantitative versus qualitative data: the numerical dimensions of drug action Biochem Pharmacol 87 2014 25 39
66. T. Kenakin, and M. Williams Defining and characterizing drug/compound function Biochem Pharmacol 87 2014 40 63
67. P.J. Tummino, and R.A. Copeland Residence time of receptor-ligand complexes and its effect on biological function Biochemistry 47 2008 5481 5492 (Pubitemid 351711169)
68. T. Costa, and A. Herz Antagonists with negative intrinsic activity at δ-opioid receptors coupled to GTP-binding proteins Proc Natl Acad Sci U S A 86 1989 7321 7325 (Pubitemid 19254452)
69. R.A. Bond, and A.P. Ijzerman Recent developments in constitutive receptor activity and inverse agonism, and their potential for GPCR drug discovery Trends Pharmacol Sci 27 2006 92 96 (Pubitemid 43184030)
70. A. Christopoulos Allosteric binding sites on cell-surface receptors: novel targets for drug discovery Nat Rev Drug Discov 1 2002 198 210 (Pubitemid 37361423)
71. R. Nussinov, and C.J. Tsai Allostery in disease and in drug discovery Cell 153 2013 293 305
72. T. Kenakin, and A. Christopoulos Signalling bias in new drug discovery: detection, quantification and therapeutic impact Nat Rev Drug Discov 12 2013 205 216
73. V.P. Torchilin Recent approaches to intracellular delivery of drugs and DNA and organelle targeting Ann Rev Biomed Engineer 8 2006 343 375 (Pubitemid 44314821)
74. C.T. Dollery Intracellular drug concentrations Clin Pharmacol Ther 93 2013 263 266
75. A. Heller, G. Brockhoff, and A. Goepferich Targeting drugs to mitochondria Eur J Pharm Biopharm 82 2012 1 18
76. A.J. Clark General pharmacology Heffner's Handbuch Der Experimentellen Pharmacologie Ergänzungsband, Band 4 1937 Springer-Verlag Berlin
77. J.H. Gaddum The action of adrenaline and ergotamine on the uterus of the rabbit J Physiol 61 1926 141 150
78. H.O. Schild Drug antagonism and pAx Pharmacol Rev 9 1957 242 246
79. E.J. Ariens Affinity and intrinsic activity in the theory of competitive inhibition Arch Int Pharmacodyn Ther 99 1954 32 49
80. R.P. Ahlquist A study of the adrenotropic receptors Am J Physiol 155 1948 586 600
81. R.P. Stephenson A modification of receptor theory Br J Pharmacol Chemother 11 1956 379 392
82. D. Mackay A general analysis of the receptor-drug interaction Br J Pharmacol 26 1966 9 16
83. D.R. Waud Pharmacological receptors Pharmacol Rev 20 1968 49 88
84. J.W. Black, and P. Leff Operational models of pharmacological agonist Proc R Soc Lond [Biol] 220 1983 141 162
85. W.D.M. Paton A theory of drug action based on the rate of drug-receptor combination Proc R Soc Lond B 154 1961 21 69
86. R.J. Lefkowitz Seven transmembrane receptors - a brief personal retrospective Biochim Biophys Acta 1768 2007 748 755 (Pubitemid 46452547)
87. T.P. Kenakin Making receptors a reality: the 2012 Nobel Prize in Chemistry Trends Pharmacol Sci 34 2013 2 5
88. D. Colquhoun Binding, gating, affinity and efficacy: the interpretation of structure-activity relationships for agonists and of the effects of mutating receptors Br J Pharmacol 125 1998 923 947 (Pubitemid 28495353)
89. T. Kenakin A pharmacology primer: theory, application and methods 3rd ed. 2009 Academic Press Burlington
90. R.S. Goody, and K.A. Johnson The original Michaelis constant: translation of the 1913 Michaelis-Menten paper. Michaelis L, Menten ML. The kinetics of invertase action Biochemistry 50 2011 8264 8269
91. J.-P. Changeux Allostery and the Monod-Wyman-Changeux model after 50 years Ann Rev Biophys 41 2012 103 133
92. D.E. Koshland Jr., G. Némethy, and D. Filmer Comparison of experimental binding data and theoretical models in proteins containing subunits Biochemistry 5 1966 365 368
93. A. DeLean, J.M. Stadel, and R.J. Lefkowitz A ternary complex model explains the agonist-specific binding properties of the adenylate cyclase-coupled beta-adrenergic receptor J Biol Chem 255 1980 7108 7117 (Pubitemid 11232874)
94. J.M. Weiss, P.H. Morgan, M.W. Lutz, and T.P. Kenakin The cubic ternary complex receptor-occupancy model II. Understanding apparent affinity J Theoret Biol 178 1996 169 182 (Pubitemid 26118846)
95. BPS/IUPHAR Guide to Pharmacology; 2013. http://www.guidetopharmacology. org/targets.jsp.
96. F. Zhu, Z. Shi, C. Qin, L. Tao, X. Liu, and F. Xu et al. Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery Nucleic Acids Res 40 2012 D1128 D1136
97. J.N. Langley On the reaction of cells and nerve-endings to certain poisons, chiefly as regards the reaction of striated muscle to nicotine and to curari J Physiol 33 1905 374 413
98. T.P. Kenakin The classification of seven transmembrane receptors in recombinant expression systems Pharmacol Rev 48 1996 413 463
99. T. Kenakin Efficacy at G-protein-coupled receptors Nat Rev Drug Discov 1 2002 103 110 (Pubitemid 41646517)
100. T.P. Kenakin New concepts in pharmacological efficacy at 7TM receptors: IUPHAR review Br J Pharmacol 168 2013 554 575
101. C.J. Langmead, and A. Christopoulos Supra-physiological efficacy at GPCRs: superstition or super agonists? Br J Pharmacol 169 2013 353 356
102. P. Cuatrecasas Membrane receptors Ann Rev Biochem 43 1974 169 214
103. G. Dahl, and T. Akerud Pharmacokinetics and the drug-target residence time concept Drug Discov Today 18 2013 697 707
104. G. Milligan Constitutive activity and inverse agonists of G protein-coupled receptors: a current perspective Mol Pharmacol 64 2003 1271 1276 (Pubitemid 37532215)
105. + Channel Tetramerization Domain-containing Protein 12 (KCTD12) J Biol Chem 288 2013 10.1074/jbc.M113.476770
106. N. Bindslev Allosteric transition: a comparison of two models BMC Pharmacol Toxicol 14 2013 4
107. T. Kenakin Drug efficacy at G protein-coupled receptors Ann Rev Pharmacol Toxicol 42 2002 349 379 (Pubitemid 34160530)
108. T. Kenakin, and L.J. Miller Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery Pharmacol Rev 62 2010 265 304
109. N. Vaidehi, and T. Kenakin The role of conformational ensembles of seven transmembrane receptors in functional selectivity Curr Opin Pharmacol 10 2010 775 781
110. P. Zhao, W. Cladman, H.H.M. Van Tol, and P. Chidiac Fine-tuning of GPCR signals by intracellular G Protein modulators Prog Mol Biol Transl Sci 115 2013 421 454
111. C.L. Schmid, and L.M. Bohn Physiological and pharmacological implications of beta-arrestin regulation Pharmacol Ther 121 2009 285 293
112. R.R. Gainetdinov, R.T. Premont, L.M. Bohn, R.J. Lefkowitz, and Caron MG: Desensitization of G protein-coupled receptors and neuronal functions Annu Rev Neurosci 27 2004 107 144 (Pubitemid 39050399)
113. E. Reiter, S. Ahn, A.K. Shukla, and R.J. Lefkowitz Molecular mechanism of β-arrestin-biased agonism at seven-transmembrane receptors Ann Rev Pharmacol Toxicol 52 2012 179 197
114. H. Shankaran, H.S. Wiley, and H. Resat Receptor downregulation and desensitization enhance the information processing ability of signalling receptors BMC Syst Biol 1 2007 48
115. J.T. Williams, S.L. Ingram, G. Henderson, C. Chavkin, M. Zastrow, and S. Schulz et al. Regulation of μ-opioid receptors: desensitization, phosphorylation, internalization, and tolerance Pharmacol Rev 65 2013 223 254
116. T. Koch, and V. Höllt Role of receptor internalization in opioid tolerance and dependence Pharmacol Ther 117 2008 199 206
117. S. Cvejic, and L. Devi Dimerization of the δ opioid receptor: implication for a role in receptor internalization J Biol Chem 272 1997 26969 27064
118. S. Angers, A. Salahpour, and M. Bouvier Dimerization: an emerging concept for G-protein-coupled receptor ontogeny and function Ann Rev Pharmacol Toxicol 42 2002 409 435 (Pubitemid 34160532)
119. G. Milligan G protein-coupled receptor dimerization: function and ligand pharmacology Mol Pharmacol 66 2004 1 7 (Pubitemid 38822080)
120. B. Stephens, and T.M. Handel Chemokine receptor oligomerization and allostery Prog Mol Biol Transl Sci 115 2013 375 420
121. M.A. Lemmon, and J. Schlessinger Regulation of signal transduction and signal diversity by receptor oligomerization Trends Biochem Sci 19 1994 459 463 (Pubitemid 24342757)
122. J. Schlessinger Ligand-induced, receptor-mediated dimerization and activation of EGF receptor Cell 110 2002 669 672 (Pubitemid 35283957)
123. M.A. Lemmon Ligand-induced ErbB receptor dimerization Exp Cell Res 315 2009 638 648
124. A. Nohe, S. Hassel, M. Ehrlich, F. Neubauer, W. Sebald, and Y.I. Henis et al. The mode of Bone Morphogenetic Protein (BMP) receptor oligomerization determines different BMP-2 signaling pathways J Biol Chem 277 2002 5330 5338 (Pubitemid 34968578)
125. J.W. Fairman, S.R. Wijerathna, M.F. Ahmad, H. Xu, R. Nakano, and S. Jha et al. Structural basis for allosteric regulation of human ribonucleotide reductase by nucleotide-induced oligomerization Nat Struct Mol Biol 18 2011 316 322
126. X. Yu, K.D. Sharma, T. Takahashi, R. Iwamoto, and E. Mekada Ligand-independent dimer formation of Epidermal Growth Factor Receptor (EGFR) is a step separable from ligand-induced EGFR signaling Mol Biol Cell 13 2002 2547 2557 (Pubitemid 34831354)
127. G.J. Babcock, M. Farzan, and J. Sodroski Ligand-independent dimerization of CXCR4, a principal HIV-1 coreceptor J Biol Chem 278 2003 3378 3385 (Pubitemid 36801253)
128. D. Pétrin, and T.E. Hébert The functional size of GPCRs - monomers, dimers or tetramers? Subcell Biochem 63 2012 67 81
129. D. Geiger, J.-L. Carpentier, P. Gorden, and L. Orci Down-regulation of insulin receptors is related to insulin internalization Exp Cell Res 185 1989 33 40 (Pubitemid 19284494)
130. S.S. Ferguson Evolving concepts in G protein-coupled receptor endocytosis: the role in receptor desensitization and signaling Pharmacol Rev 53 2001 1 24 (Pubitemid 32173106)
131. C.A. Moore, S.K. Milano, and J.L. Benovic Regulation of receptor trafficking by GRKs and arrestins Annu Rev Physiol 69 2007 451 482 (Pubitemid 46457651)
132. A. Sorkin, and M. von Zastrow Signal transduction and endocytosis: close encounters of many kinds Nat Rev Mol Cell Biol 3 2002 600 614
133. D.S. Kang, X. Tian, and J.L. Benovic β-Arrestins and G protein-coupled receptor trafficking Methods Enzymol 521 2013 91 108
134. M.J. Amaya, A.G. Oliveira, E.S. Guimarães, M.C.F. Casteluber, S.M. Carvalho, and L.M. Andrade et al. The insulin receptor translocates to the nucleus to regulate cell proliferation in liver Heptalogy 2013 10.1002/hep.26609
135. G.L. Collingridge, J.T.R. Isaac, and Y.T. Wang Receptor trafficking and synaptic plasticity Nat Rev Neurosci 5 2004 952 962 (Pubitemid 39593358)
136. T. Araud, S. Wonnacott, and D. Bertrand Associated proteins: the universal toolbox controlling ligand gated ion channel function Biochem Pharmacol 80 2010 160 169
137. S. Galandrin, G. Oligny-Longpre, and M. Bouvier The evasive nature of drug efficacy: implications for drug discovery Trends Pharmacol Sci 28 2007 423 430 (Pubitemid 47087968)
138. T. Kenakin Functional selectivity and biased receptor signaling J Pharmacol Exp Ther 336 2010 296 302
139. E.J. Whalen, S. Rajagopal, and R.J. Lefkowitz Therapeutic potential of β-arrestin and G protein-biased agonists Trends Mol Med 17 2011 126 139
140. K. Mullane, R.J. Winquist, and M. Williams The translational paradigm in drug discovery Biochem Pharmacol 87 2014 189 210
141. T. Evron, T.L. Daigle, and M.G. Caron GRK2: multiple roles beyond G protein-coupled receptor desensitization Trends Pharmacol Sci 33 2012 154 164
142. C. Ribas, P. Penela, C. Murga, A. Salcedo, C. García-Hoz, and M. Jurado-Pueyo The G protein-coupled receptor kinase (GRK) interactome: role of GRKs in GPCR regulation and signaling Biochim Biophys Acta 1768 2007 913 922 (Pubitemid 46452540)
143. J.R. Hepler RGS protein and G protein interactions: a little help from their friends Mol Pharmacol 64 2003 547 549 (Pubitemid 37048556)
144. J.B. Blumer, M.J. Cismowski, M. Sato, and S.M. Lanier AGS proteins: receptor-independent activators of G-protein signaling Trends Pharmacol Sci 26 2005 470 476 (Pubitemid 41207879)
145. J.B. Blumer, A.V. Smrcka, and S.M. Lanier Mechanistic pathways and biological roles for receptor-independent activators of G-protein signaling Pharmacol Ther 113 2007 488 506 (Pubitemid 46389413)
146. P.A. Poole-Wilson, K. Swedberg, J.G. Cleland, A. Di Lenarda, P. Hanrath, and M. Komajda et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial Lancet 362 2003 7 13 (Pubitemid 36835815)
147. J.W. Wisler, S.M. DeWire, E.J. Whalen, J.D. Violin, M.T. Drake, and S. Ahn et al. A unique mechanism of β-blocker action: carvedilol stimulates β-arrestin signaling Proc Natl Acad Sci U S A 104 2007 16657 16662 (Pubitemid 350211072)
148. A. Vroon, C.J. Heijnen, and A. Kavelaars GRKs and arrestins: regulators of migration and inflammation J Leukoc Biol 80 2006 1214 1221 (Pubitemid 44904958)
149. H.O. Onaran, A. Scheer, S. Cotecchia, and T. Costa A look at receptor efficacy. From the signaling network of the cell to the intramolecular motion of the receptor Handbook Exp Pharmacol 148 2002 217 280
150. J.A. O'Brien, W. Lemaire, T.-B. Chang, R.S.L. Chang, M.A. Jacobson, and S.N. Ha et al. A family of highly selective allosteric modulators of the metabotropic glutamate receptor subtype 5 Mol Pharmacol 64 2003 731 740 (Pubitemid 37048578)
151. D.A. Hall Modeling the functional effects of allosteric modulators at pharmacological receptors: an extension of the two-state model of receptor activation Mol Pharmacol 58 2000 1412 1423
152. H. Mohler, and T. Okada Benzodiazepine receptor: demonstration in the central nervous system Science 198 1977 849 851 (Pubitemid 8214700)
153. A agonists and partial agonists: THIP (Gaboxadol) as a non-opioid analgesic and a novel type of hypnotic Biochem Pharmacol 68 2004 1573 1580 (Pubitemid 39286462)
154. P.D. Suzdak, and J.A. Jansen A review of the preclinical pharmacology of tiagabine: a potent and selective anticonvulsant GABA uptake inhibitor Epilepsia 36 1995 612 626
155. G. Milligan Oligomerisation of G-protein-coupled receptors J Cell Sci 114 2001 1265 1271 (Pubitemid 32409463)
156. B. Bengsch, B. Seigel, M. Ruhl, J. Timm, and M. Kuntz et al. Coexpression of PD-1, 2B4, CD160 and KLRG1 on exhausted HCV-specific CD8+ T cells is linked to antigen recognition and T cell differentiation PLoS Pathog 6 2010 e1000947
157. H. Husi, M.A. Ward, J.S. Choudary, W.P. Blackstock, and S.G.N. Grant Proteomic analysis of NMDA receptor-adhesion protein signaling complexes Nat Neurosci 3 2000 661 669 (Pubitemid 30437200)
158. 7 receptor signalling complex EMBO J 20 2001 6347 6358 (Pubitemid 33078708)
159. H.H. Dale The action of certain esters and ethers of choline, and their relation to muscarine J Pharm Exp Ther 6 1914 174 190
160. R.R. Neubig, M. Spedding, T. Kenakin, and A. Christopoulos International union of pharmacology committee on receptor nomenclature and drug classification. XXXVIII. Update on terms and symbols in quantitative pharmacology Pharmacol Rev 55 2003 597 606 (Pubitemid 37500521)
161. De Jongh DK, quoted by Maehle A-H. A binding question: the evolution of the receptor concept. Endeavour 2009;33:134-9.
162. R.P. Ahlquist Adrenergic receptors: a personal and practical view Persp Biol Med 1973 119 122
163. G.A. Robison, R.W. Butcher, and E.W. Sutherland Adenyl cyclase as an adrenergic receptor Ann N Y Acad Sci 139 1967 703703
164. D. Nachmansohn Chemical and molecular basis of nerve activity 1959 Academic Press New York, NY
165. J.P. Changeux, and S.J. Edelstein Nicotinic acetylcholine receptors. From molecular biology to cognition 2005 Odile Jacob New York
166. P.G. Waser The cholinergic receptor J Pharm Pharmacol 12 1960 577 594
167. R. Miledi, P. Molinoff, and L.T. Potter Isolation of the cholinergic receptor protein of Torpedo electric tissue Nature 229 1971 554 557
168. P.-J. Corringer, and J.-P. Changeux Nicotinic acetylcholine receptors Scholarpedia 3 2008 3468
169. P.A. Hargrave The large scale preparation of rhodopsin Vision Res 16 1976 1013 1014
170. P. Cuatrecasas, and M.D. Hollenberg Membrane receptors and hormone action Adv Protein Chem 30 1976 251 451
171. R.G.L. Shorr, R.J. Lefkowitz, and M.G. Caron Purification of the β-adrenergic receptor J Biol Chem 256 1981 5820 5826
172. J.L. Benovic, R.G. Shorr, M.G. Caron, and R.J. Lefkowitz The mammalian β2-adrenergic receptor: purification and characterization Biochemistry 23 1984 4510 4518 (Pubitemid 14012267)
173. J.W. Black Ahlquist and the development of beta-adrenoceptor antagonists Postgrad Med J 52 Suppl. 4 1976 11 13
174. A.-H. Maehle A binding question: the evolution of the receptor concept Endeavour 33 2009 134 139
175. R.S. Yalow, and S.A. Berson Immunoassay of endogenous plasma insulin in man J Clin Invest 39 1960 1157 1175
176. I. Pastan, J. Roth, and V. Macchia Binding of hormone to tissue: the first step in polypeptide hormone action Proc Natl Acad Sci U S A 56 1966 1802 1809
177. R.J. Lefkowitz, J. Roth, and I. Pastan Radioreceptor assay of adrenocorticotropic hormone: new approach to assay of polypeptide hormones in plasma Science 170 1970 633 635
178. P. Cuatrecasas Insulin-receptor interactions in adipose tissue cells: direct measurement and properties Proc Natl Acad Sci U S A 68 1971 1264 1268
179. R.J. Lefkowitz, E. Haber, and D. O'Hara Identification of the cardiac beta-adrenergic receptor protein: solubilization and purification by affinity chromatography Proc Natl Acad Sci U S A 69 1972 2828 2832
180. C.D. Pert, and S.H. Snyder Opiate receptor: demonstration in nervous tissue Science 179 1973 1011 1014
181. 3H] etorphine to rat-brain homogenate Proc Natl Acad Sci U S A 70 1973 1947 1949
182. S.E. Cozzens Social control and multiple discovery in science: the opiate receptor case 1989 State University of New York Press Albany, NY
183. B.M. Cox Recent developments in the study of opioid receptors Mol Pharmacol 83 2013 723 728
184. D.B. Bylund, and M.L. Toews Radioligand binding methods: practical guide and tips Am J Physiol Lung Physiol 265 1993 L421 L429
185. 3H]epibatidine binding to nicotinic cholinergic receptors in rat and human brain Mol Pharmacol 48 1995 280 287
186. 3H] 3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid to rat brain membranes: a selective, high-affinity ligand for N-methyl-d-aspartate receptors J Pharmacol Exp Ther 240 1987 778 784 (Pubitemid 17043574)
187. I. Creese, D.R. Burt, and S.H. Snyder Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs Science 192 1976 481 483
188. S.J. Enna, and S.H. Snyder Properties of γ-aminobutyric acid (GABA) receptor binding in rat brain synaptic membrane fractions Brain Res 100 1975 81 97
189. A.B. Young, and S.H. Snyder Strychnine binding associated with glycine receptors of the central nervous system Proc Natl Acad Sci U S A 70 1973 2832 2836
190. H.I. Yamamura, and S.H. Snyder Muscarinic cholinergic binding in rat brain Proc Natl Acad Sci U S A 71 1974 1725 1729
191. J.P. Bennett Jr., and S.H. Snyder Stereospecific binding of d-lysergic acid diethylamide (LSD) to brain membranes: relationship to serotonin receptors Brain Res 94 1975 523 544
192. 3H] spiroperidol Mol Pharmacol 16 1979 687 699 (Pubitemid 10203525)
193. D.B. Bylund, and S.H. Snyder Beta adrenergic receptor binding in membrane preparations from mammalian brain Mol Pharmacol 12 1976 568 580
194. R.J. Lefkowitz, and L.T. Williams Catecholamine binding to the beta-adrenergic receptor Proc Natl Acad Sci U S A 74 1977 515 519
195. S.H. Snyder Dopamine receptors, neuroleptics and schizophrenia Am J Psychiatr 138 1981 460 464
196. R. Zhang, and X. Xie Tools for GPCR drug discovery Acta Pharmacol Sin 33 2012 372 384
197. S.C. Rogan, and B.L. Roth Remote control of neuronal signaling Pharmacol Rev 63 2011 291 315
198. A.M. Packer, B. Roska, and M. Häusser Targeting neurons and photons for optogenetics Nat Neurosci 16 2013 805 815
199. 3H]-adenosine, a stable analog of adenosine Proc Natl Acad Sci U S A 77 1980 6892 6896 (Pubitemid 11172541)
200. R.F. Bruns, J.W. Daly, and S.H. Snyder Adenosine receptors in brain membranes: binding of N6-cyclohexyl[3H]adenosine and 1,3-diethyl-8-[3H] phenylxanthine Proc Natl Acad Sci U S A 77 1980 5547 5551 (Pubitemid 11249682)
201. M.J. Kuhar, E.B. De Souza, and J.R. Unnerstall Receptor mapping by autoradiography and other methods Ann Rev Neurosci 9 1986 27 59 (Pubitemid 16055779)
202. M. Stanley, and J.J. Mann Increased serotonin-2 binding sites in frontal cortex of suicide victims Lancet 1 1983 214 216 (Pubitemid 13171106)
203. J.P. Bennett Jr., S.J. Enna, D.B. Bylund, J.C. Gillin, R.J. Wyatt, and S.H. Snyder Neurotransmitter receptors in frontal cortex of schizophrenics Arch Gen Psychiatry 36 1979 927 934 (Pubitemid 10121036)
204. A receptor changes in Alzheimer's disease Neurosci Lett 82 1987 246 252 (Pubitemid 17159134)
205. S.D. Katugampola, and A.P. Davenport Thromboxane receptor density is increased in human cardiovascular disease with evidence for inhibition at therapeutic concentrations by the AT1 receptor antagonist losartan Br J Pharmacol 134 2001 1385 1392 (Pubitemid 33131888)
206. 2+ channel/ryanodine receptor: modulation by endogenous effectors, drugs and disease states Pharmacol Rev 49 1997 1 52
207. J. Gagné, M. Milot, S. Gélinas, A. Lahsaïni, F. Trudeau, and M.G. Martinoli et al. Binding properties of glutamate receptors in streptozotocin-induced diabetes in rats Diabetes 46 1997 841 846 (Pubitemid 27188262)
208. P. Cuatrecasas, and M.D. Hollenberg Binding of insulin and other hormones to non-receptor materials: saturability, specificity and apparent "negative cooperativity" Biochem Biophys Res Commun 1975 31 41
209. A. Essali, N.A.-H. Haasan, C. Chunbo Li, and J. Rathbone Clozapine versus typical neuroleptic medication for schizophrenia Cochrane Libr 2009 CD000059.pub2
210. B.L. Roth, D.J. Sheffler, and W.K. Kroeze Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia Nat Rev Drug Discov 3 2004 353 359 (Pubitemid 38499762)
211. M. Humbert-Claude, E. Davenas, F. Gbahou, L. Vincent, and J.-M. Arrang Involvement of histamine receptors in the atypical antipsychotic profile of clozapine: a reassessment in vitro and in vivo Psychopharmacology 220 2012 225 241
212. R. Røge, B.K. Møller, C.R. Andersen, C.U. Correll, and J. Nielsen Immunomodulatory effects of clozapine and their clinical implications: what have we learned so far? Schizophr Res 140 2012 204 213
213. 3H) diazepam binding Proc Natl Acad Sci U S A 74 1977 3805 3809 (Pubitemid 8189972)
214. A. Closse, W. Frick, A. Dravid, G. Bolliger, D. Hauser, and A. Sauter et al. Classification of drugs according to receptor binding profiles Naunyn-Schmiedeberg's Arch Pharmacol 327 1984 95 101 (Pubitemid 14066534)
215. D. Horvath, and C. Jeandenans Neighborhood behavior of in silico structural spaces with respect to in vitro activity spaces - a novel understanding of the molecular similarity principle in the context of multiple receptor binding profiles J Chem Inf Comput Sci 43 2003 680 690
216. J. Bowes, A.J. Brown, J. Hamon, W. Jarolimek, A. Sridhar, and G. Waldron et al. Reducing safety-related drug attrition: the use of in vitro pharmacological profiling Nat Rev Drug Discov 11 2012 909 922
217. S.J. Peroutka, and S.H. Snyder Antiemetics: neurotransmitter receptor binding predicts therapeutic actions Lancet 319 1982 658 659 (Pubitemid 12179938)
218. D. Rampe, and A.M. Brown A history of the role of the hERG channel in cardiac risk assessment J Pharmacol Toxicoll Methods 68 2013 13 22
219. A. Dove High-throughput screening goes to school Nat Methods 4 2007 523 532 (Pubitemid 46852079)
220. R.T. Strachan, G. Ferrara, and B.L. Roth Screening the receptorome: an efficient approach for drug discovery and target validation Drug Discov Today 11 2006 708 716 (Pubitemid 44038633)
221. P.M. Sweetnam, L. Caldwell, J. Lancaster, C. Bauer Jr., B. McMillan, and W.J. Kinnier et al. The role of receptor binding in drug discovery J Nat Prod 56 1993 441 455 (Pubitemid 23129606)
222. S.W. Duric, I. Akritopoulou-Zanze, P.B. Cox, and S. Galasinski Compound collection enhancement and paradigms for high-throughput screening - an update Ann Rep Med Chem 45 2010 409 428
223. R. Macarron, M.N. Banks, D. Bojanic, D.J. Burns, D.A. Cirovic, and T. Garyantes et al. Impact of high-throughput screening in biomedical research Nat Rev Drug Discov 10 2011 188 195
224. A. Dove Screening for content - the evolution of high throughput Nat Biotechnol 21 2003 859 864 (Pubitemid 36936186)
225. M.E. Schurdak, M.J. Voorbach, L. Gao, X. Cheng, K.M. Comess, and S.M. Rottinghaus et al. Complex gel permeation assays for screening combinatorial libraries J Biomol Screen 6 2001 313 323 (Pubitemid 33027498)
226. J.J. Agrestia, E. Antipov, A.R. Abate, K. Ahn, A.C. Rowat, and J.-C. Barete et al. Ultra high-throughput screening in drop-based microfluidics for directed evolution Proc Natl Acad Sci U S A 107 2010 4004 4009
227. C.A. Lipinski, F. Lombardo, B.W. Dominy, and P.J. Feeney Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings Adv Drug Deliv Rev 46 2001 3 26 (Pubitemid 33653411)
228. J.A. Lee, M.T. Uhlik, C.M. Moxham, D. Tomandl, and D.J. Sall Modern phenotypic drug discovery is a viable, neoclassic pharma strategy J Med Chem 55 2012 4527 4538
229. J. Dunlop, M. Bowlby, R. Peri, D. Vasilyev, and R. Arias High-throughput electrophysiology: an emerging paradigm for ion-channel screening and physiology Nat Rev Drug Discov 7 2008 358 368
230. C.M. Hempel, M. Sivula, J.M. Levenson, D.M. Rose, and B. Li et al. A system for performing high throughput assays of synaptic function PLoS ONE 6 2011 e25999
231. R.A. Cerione, D.R. Sibley, J. Codina, J.L. Benovic, J. Winslow, and E.J. Neer et al. Reconstitution of a hormone-sensitive adenylate cyclase system. The pure beta-adrenergic receptor and guanine nucleotide regulatory protein confer hormone responsiveness on the resolved catalytic unit J Biol Chem 259 1984 9979 9982 (Pubitemid 14067662)
232. J.M. Herz, W.J. Thomsen, and G.G. Yarbrough Molecular approaches to receptors as targets for drug discovery J Recept Signal Transduct Res 17 1997 671 776 (Pubitemid 27381429)
233. N. Nash Overview of receptor cloning Curr Protocol Pharmacol 1998 6.1
234. J. Giraudat, A. Devillers-Thiery, C. Auffray, F. Rougeon, and J.-P. Changeaux Identification of a cDNA clone coding for the acetylcholine binding subunit of Torpedo marmorata acetylcholine receptor EMBO J 1 1982 713 717
235. J. Nathans, and D.S. Hogness Isolation and nucleotide sequence of the gene encoding human rhodopsin Proc Natl Acad Sci U S A 81 1984 4851 4855 (Pubitemid 14066213)
236. R.A.F. Dixon, B.K. Kobilka, D.J. Strader, J.L. Benovic, H.G. Dohlman, and T. Frielle et al. Cloning of the gene and cDNA for mammalian β-adrenergic receptor and homology with rhodopsin Nature 321 1986 75 79 (Pubitemid 16080889)
237. G. Benoit, A. Cooney, V. Giguere, H. Ingraham, M. Lazar, and G. Muscat et al. International union of pharmacology. LXVI. Orphan nuclear receptors Pharmacol Rev 58 2006 798 836 (Pubitemid 44833747)
238. M. Hanner, F.F. Moebius, A. Flandorfer, H.G. Knaus, J. Striessnig, and E. Kempner et al. Purification, molecular cloning, and expression of the mammalian sigma 1-binding site Proc Natl Acad Sci U S A 93 1996 8072 8077 (Pubitemid 26277167)
239. P. Seth, Y.-J. Hui, W. Li, W. Huang, F.H. Leibach, and V. Ganapathy Cloning and functional characterization of a sigma receptor from rat brain J Neurochem 70 1998 922 931 (Pubitemid 28113624)
240. T. Maurice, and T.P. Su The pharmacology of sigma-1 receptors Pharmacol Ther 124 2009 195 206
241. J. Xu, C. Zeng, W. Chu, F. Pan, J.M. Rothfuss, and F. Zhang Identification of the PGRMC1 protein complex as the putative sigma-2 receptor binding site Nat Commun 2 2011 380
242. 2 receptor J Pharmacol Exp Ther 276 1996 289 297 (Pubitemid 26150970)
243. A.O. Davenport, S.H.P. Alexander, J.L. Sharman, A.J. Pawson, H.E. Benson, and A.E. Monaghan International Union of Basic and Clinical Pharmacology. LXXXVIII. G protein-coupled receptor list: recommendations for new pairings with cognate ligands Pharmacol Rev 65 2013 967 986
244. O. Civelli Orphan GPCRs and neuromodulation Neuron 76 2012 12 21
245. O. Civelli, R.K. Reinscheid, Y. Zhang, Z. Wang, R. Fredriksson, and H.B. Schiöth G protein-coupled receptor deorphanizations Ann Rev Pharmacol Toxicol 53 2013 127 146
246. R. Fredriksson, M.C. Lagerström, L.-G. Lundin, and H.B. Schiöth The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints Mol Pharmacol 63 2003 1256 1272 (Pubitemid 36627220)
247. M.C. Lagerstrom, and H.B. Schioth Structural diversity of G protein-coupled receptors and significance for drug discovery Nat Rev Drug Discov 7 2008 339 357
248. M. Blomenröhr, H.F. Vischer, and J. Bogerd Receptor mutagenesis strategies for examination of structure-function relationships Methods Mol Biol 259 2004 307 322
249. B.K. Kobilka, T.S. Kobilka, K. Daniel, J.W. Regan, M.G. Caron, and R.J. Lefkowitz Chimeric alpha 2, beta 2-adrenergic receptors: delineation of domains involved in effector coupling and ligand binding specificity Science 240 1988 1310 1316
250. J. Wess, K. Nakajima, and S. Jain Novel designer receptors to probe GPCR signaling and physiology Trends Pharmacol Sci 34 2013 385 392
251. J.A. Salon, D.T. Lodowski, and K. Palczewski The significance of G Protein-coupled receptor crystallography for drug discovery Pharmacol Rev 63 2011 901 937
252. + conduction and selectivity Science 280 1998 69 77 (Pubitemid 28169082)
253. K. Palczewski, T. Kumasaka, T. Hori, C.A. Behnke, H. Motoshima, and B.A. Fox et al. Crystal structure of rhodopsin: a G protein-coupled receptor Science 289 2000 739 745 (Pubitemid 30650186)
254. 2-adrenergic G-protein-coupled receptor Nature 450 2007 383 387 (Pubitemid 350126755)
255. A.D. Corbett, G. Henderson, A.T. McKnight, and S.J. Paterson 75 years of opioid research: the exciting but vain quest for the Holy Grail Br J Pharmacol 147 Suppl 1 2006 S153 S162
256. V. Katritch, V. Cherezov, and R.C. Stevens Structure-function of the G protein-coupled receptor superfamily Ann Rev Pharmacol Toxicol 53 2013 531 556
257. I. Tickle, A. Sharff, M. Vinkovic, J. Yon, and H. Jhoti High-throughput protein crystallography and drug discovery Chem Soc Rev 33 2004 558 565 (Pubitemid 39540519)
258. D.E. Danley Crystallization to obtain protein-ligand complexes for structure-aided drug design Acta Crystallogr D Biol Crystallogr 62 2006 569 575 (Pubitemid 43806633)
259. A.M. Hassell, G. An, R.K. Bledsoe, J.M. Bynum, H.L. Carter III, and S.-J.J. Deng et al. Crystallization of protein-ligand complexes Acta Crystallogr D Biol Crystallogr 63 2007 72 79 (Pubitemid 46141482)
260. G. Seddon, V. Lounnas, R. McGuire, T. van den Bergh, R.P. Bywater, and L. Oliveira et al. Drug design for ever, from hype to hope J Comput-Aided Mol Des 26 2012 137 150
261. S.B. Shuker, P.J. Hajduk, R.P. Meadows, and S.W. Fesik Discovering high-affinity ligands for proteins: SAR by NMR Science 274 1996 1531 1534 (Pubitemid 26403929)
262. M.J. Harner, A.O. Frank, and S.W. Fesik Fragment-based drug discovery using NMR spectroscopy J Biomol NMR 56 2013 65 75
263. G.K. Akbar, V.R. Dasari, T.E. Webb, K. Ayyanathan, K. Pillarisetti, and A.K. Sandhu et al. Molecular cloning of a novel P2 purinoceptor from human erythroleukemia cells J Biol Chem 271 1996 18363 18367 (Pubitemid 26322690)
264. C.L. Herold, Q. Li, J.B. Schachter, T.K. Harden, and R.A. Nicholas Lack of nucleotide-promoted second messenger signaling responses in 1321N1 cells expressing the proposed P2Y receptor, p2y7 Biochem Biophys Res Commun 235 1997 717 721 (Pubitemid 27326550)
265. T. Yokomizo, T. Izumi, K. Chang, Y. Takuwa, and T. Shimizu A G-protein-coupled receptor for leukotriene B4 that mediates chemotaxis Nature 387 1997 620 624 (Pubitemid 27248768)
266. Harpold MM, Brust P. Assay methods and compositions useful for measuring the transduction of an intracellular signal. US Patent 5,401,629; 1995.
267. G.J. Flattman, and J.M. Kaplan Licensing research tool patents Nat Biotechnol 20 2002 945 947
268. R. Huang, N. Southall, Y. Wang, A. Yasgar, P. Shinn, and A. Jadhav et al. The NCGC pharmaceutical collection: a comprehensive resource of clinically approved drugs enabling repurposing and chemical genomics Sci Transl Med 3 2011 80ps16
269. J. Schmutz, J. Wheeler, J. Grimwood, M. Dickson, J. Yang, and C. Caoile et al. Quality assessment of the human genome sequence Nature 429 2004 365 368 (Pubitemid 38715122)
270. E.R. Mardis Next-Generation Sequencing Platforms Annu Rev Anal Chem 6 2013 287 303
271. D.H. Roukos Next-generation, genome sequencing-based biomarkers: concerns and challenges for medical practice Biomarker Med 4 2010 583 586
272. A.C.J.W. Janssens, and C.M. van Duijn Genome-based prediction of common diseases: methodological considerations for future research Genome Med 1 2009 20
273. R. Kramer, and D. Cohen Functional genomics to new drug targets Nat Rev Drug Discov 3 2004 965 972 (Pubitemid 39529932)
274. A.D. Wist, S.I. Berger, and R. Iyengar Systems pharmacology and genome medicine: a future perspective Genome Med 1 2009 11
275. F.S. Collins, E.D. Green, A.E. Guttmacher, and M.S. Guyer US National Human Genome Research Institute. A vision for the future of genomics research Nature 422 2003 835 847 (Pubitemid 36520032)
276. J. Le Fanu The rise and fall of modern medicine 2nd ed. 2011 Abacus London 454 464
277. F.S. Collins Has the revolution arrived? Nature 464 2010 674 675
278. L.B. Alexandrov, S. Nik-Zainal, D.C. Wedge, S.A.J.R. Aparicio, S. Behjati, and A.V. Biankin et al. Signatures of mutational processes in human cancer Nature 2013 [ePub August 14]
279. P.D.P. Pharoah, Y.-Y. Tsai, S.J. Ramus, C.M. Phelan, E.L. Goode, and K. Lawrenson GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer Nat Genet 45 2013 362 370
280. S.R. Brant Promises, delivery and challenges of inflammatory bowel disease risk disease discovery Clin Gastroenterol Hepatol 11 2013 22 26
281. B. Khor, A. Gardet, and R.J. Xavier Genetics and pathogenesis of inflammatory bowel disease Nature 474 2011 307 317
282. M.A. Rivas, M. Beaudoin, A. Gardet, C. Stevens, Y. Sharma, and C.K. Zhang et al. Deep resequencing of GWAS loci identifies independent rare variants associated with inflammatory bowel disease Nat Genet 43 2011 1066 1073
283. S. Jones, X. Zhang, D.W. Parsons, J.C.-H. Lin, R.J. Leary, and P. Angenendt et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses Science 321 2008 1801 1806
284. D.W. Parsons, S. Jones, X. Zhang, J.C.-H. Lin, R.J. Leary, and P. Angenendt et al. An integrated genomic analysis of human glioblastoma multiforme Science 321 2008 1807 1812
285. T. O'Hare, and C.A. Eide Deininger MWN Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia Blood 110 2007 2242 2249 (Pubitemid 47523141)
286. P. Workman, B. Al-Lazikani, and P.A. Clarke Genome-based cancer therapeutics: targets, kinase drug resistance and future strategies for precision oncology Curr Opin Pharmacol 13 2013 486 496
287. D. MacArthur Methods: face up to false positives Nature 487 2012 427 428
288. M.S. Lawrence, P. Stojanov, P. Polak, G.V. Kryukov, K. Cibulskis, and A. Sivachenko et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes Nature 499 2013 214 218
289. M. Gerlinger, A.J. Rowan, S. Horswell, J. Larkin, D. Endesfelder, and E. Gronroos et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing N Engl J Med 366 2012 883 892
290. K. Strange The end of "naIve reductionism": rise of systems biology or renaissance of physiology? Am J Physiol Cell Physiol 288 2005 C968 C974
291. M. Rask-Andersen, M.S. Almén, and H.B. Schiöth Trends in the exploitation of novel drug targets Nat Rev Drug Discov 10 2011 579 590
292. M. Iskar, G. Zeller, X.-M. Zhao, V. van Noort, and P. Bork Drug discovery in the age of systems biology: the rise of computational approaches for data integration Curr Opin Biotechnol 23 2012 609 616
293. J.V. Olsen, M. Vermeulen, A. Santamaria, C. Kumar, M.L. Miller, and L.J. Jensen et al. Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis Sci Signal 3 2010 ra3
294. A. Derouiche, C. Cousin, and I. Mijakovic Protein phosphorylation from the perspective of systems biology Curr Opin Biotechnol 23 2012 585 590
295. A. Mullard Drug repurposing programmes get lift off Nat Rev Drug Discov 11 2011 505 506
296. D.J. Wild, Y. Ding, A.P. Sheth, L. Harland, E.M. Gifford, and M.S. Lajiness Systems chemical biology and the Semantic Web: what they mean for the future of drug discovery research Drug Discov Today 17 2012 469 474
297. M. Schenone, V. Dančík, B.K. Wagner, and P.A. Clemons Target identification and mechanism of action in chemical biology and drug discovery Nature Chem Biol 9 2013 232 240
298. PCAST - President's Council of Advisors on Science and Technology Report to the President on propelling innovation in drug discovery, development, and evaluation 2012 http://www.whitehouse.gov/sites/default/files/microsites/ostp/ pcast-fda-final.pdf
299. J. Rung, and A. Brazma Reuse of public genome-wide gene expression data Nat Rev Genet 14 2013 89 99
300. B. Goldacre Bad medicine 2012 Fourth Estate London 1 99
301. T. Kenakin A pharmacology primer: theory, application and methods 3rd ed. 2009 Academic Press Burlington xv
302. Y. Lazebnik Can a biologist fix a radio? - Or, what I learned while studying apoptosis Cancer Cell 2 2002 179 182 (Pubitemid 41043973)
303. E. Pennisi ENCODE project writes euology for Junk DNA Science 337 2012 1159 1160
304. C. DeLisi Guest editorial: systems biology, the second time around Environ Health Perspect 112 2004 A926 A927
305. H. Kubinyi Drug research: myths, hype and reality Nat Rev Drug Discov 2 2003 665 668 (Pubitemid 37368830)
306. D. Shaywitz, and N. Taleb Drug research needs serendipity 2008 Financial Times http://www.ft.com/intl/cms/s/0/b735787c-5d9b-11dd-8129-000077b07658.html
307. P. McGonigle, and B.A. Ruggeri Animal models of human disease: challenges in enabling translation Biochem Pharmacol 87 2014 162 171
308. A.L. Demain History of industrial biotechnology W. Soetaert, E.J. Vandamme, Industrial biotechnology. Sustainable growth and economic success 2010 Wiley VCH Weinheim 17 77
309. G.P. Pisano Science business: the promise, the reality, and the future of biotech 2006 Harvard Business School Press Cambridge, MA
310. J. Black Drugs from emasculated hormones: the principle of syntopic antagonism Science 245 1989 486 493 (Pubitemid 19203998)
311. M.J.A. Walker The major impacts of James Black's drug discoveries on medicine and pharmacology Trends Pharmacol Sci 32 2011 183 188
312. P. Cuatrecasas Industry-University alliances in biomedical research J Clin Pharamcol 32 1992 100 106
313. P.R. Vagelos Social benefits of a successful biomedical research company: Merck Proc Am Philos Soc 145 2001 575 578
314. B. Zycher, J.A. DiMasi, and C.-P. Milne The truth about drug innovation: thirty-five summary case histories on private sector contributions to pharmaceutical science. Medical Progress Report 2008 Manhattan Institute for Policy Research http://www.manhattan-institute.org/html/mpr-06.htm
315. R.A. Maxwell, and S.B. Eckhardt Drug discovery. A casebook and analysis 1990 Humana Clifton, NJ 414
316. J. Black A personal perspective on Dr. Paul Janssen J Med Chem 48 2005 1687 1688
317. P.J. Lewi, and A. Smith Successful pharmaceutical discovery: Paul Janssen's concept of drug research R&D Manage 37 2007 355 361
318. T.H. Stanley, T.D. Egan, and H. Van Aken A tribute to Dr. Paul A.J. Janssen: entrepreneur extraordinaire, innovative scientist, and significant contributor to anesthesiology Anesth Analg 106 2008 451 462
319. J. Uitdehaag Where is the optimism? Warrior teachings to regain the drug discovery spirit Drug Discov Today 12 2007 105 107 (Pubitemid 46188407)
320. P.J. Lewi The conductor and his orchestra Drug Discov Today 13 2008 281 284
321. D.T. Wong, K.W. Perry, and F.P. Bymaster Case history: the discovery of fluoxetine hydrochloride (Prozac) Nat Rev Drug Discov 4 2005 764 774 (Pubitemid 43090497)
322. B.H. Munos, and W.W. Chin How to revive breakthrough innovation in the pharmaceutical industry Sci Transl Med 3 2011 89cm16
323. B. Munos A forensic analysis of drug targets from 2000 through 2012 Clin Pharmacol Ther 94 2013 407 411
324. M.A. Murcko, and P. Walters Alpha shock J Comput Aided Mol Des 26 2012 97 102
325. S.J. Enna, and M. Williams Challenges in the search for drugs to treat central nervous system disorders J Pharmacol Exp Ther 329 2009 404 411
326. B.J. Marshall, and J.R. Warren Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration Lancet 323 1984 1311 1315
327. ENCODE Project Consortium An integrated encyclopedia of DNA elements in the human genome Nature 489 2012 57 74
328. D. Graur, Y. Zheng, N. Price, R.B.R. Azevedo, R.A. Zufall, and E. Elhaik On the immortality of television sets: "function" in the human genome according to the evolution-free gospel of ENCODE Genome Biol Evolut 5 2013 578 590
329. M. Marino The use and misuse of statistical methodologies in pharmacology research Biochem Pharmacol 87 2014 78 92
330. D.C. Anderson, and K. Kodulka Biomarkers in pharmacology and drug discovery Biochem Pharmacol 87 2014 172 188